MaxCyte Regains Nasdaq Compliance, Resolving Bid Price Deficiency
MXCT sits 77% above its 52-week low of $0.643.
Summary
MaxCyte has successfully regained compliance with Nasdaq's minimum $1.00 bid price requirement, as confirmed by Nasdaq on June 10, 2026. This positive development resolves the non-compliance notice the company received in March 2026, which had initiated delisting procedures. The stock maintained a closing bid price above $1.00 for ten consecutive business days, effectively closing the matter and removing the immediate delisting threat.
At the time of this announcement, MXCT was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.1M. The 52-week trading range was $0.64 to $2.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.